Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Anti-CD20 CAR-T in CD20+ Lymphoma
NCT02965157Phase 2Unknown
- Sponsor
- Bodihekang
- Start
- Aug 2016
- Primary completion
- Jan 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of C-CAR066 in B cell lymphoma, sponsored by Bodihekang. Primary endpoint: All Cause Mortality at 1 year. Status: unknown.
02
Drugs
C-CAR066
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02965157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965157.